We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scapa Group Plc | LSE:SCPA | London | Ordinary Share | GB0007281198 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 214.50 | 214.50 | 215.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSCPA
RNS Number : 8234B
Scapa Group PLC
13 October 2020
13 October 2020
LEI No. 213800QIPVTK5ES5UU36
Scapa Group plc
Period end update
Scapa Group plc (AIM: SCPA) is today providing an unaudited period end update for the six months ended 30 September 2020.
Further to the AGM statement of August 2020, Scapa Group has continued to track ahead of its COVID plan. Scapa now anticipates that FY21 H1 Group revenues will be ahead of the Board's expectations. Revenues for the Industrial division are expected to close c.22% less than prior year. In Healthcare, revenues are expected to be c.23% less than prior year (excluding ConvaTec)(2). As previously indicated, Scapa acted swiftly to implement structural costs changes across the business in response to the impact of the COVID-19 pandemic on the reduction in product demand, participated in various government assistance programs and ensured variable costs were closely managed to match.
H1 Statutory Basis H1 Continuing Change Basis(1) Statutory Continuing GBPm FY21 FY20 FY21 FY20 Basis Basis(1) ---------- --------- ------- ------- ---------- ----------- Healthcare Revenues(2) 55.1 74.7 51.4 71.1 -26.2% -27.6% ---------- --------- ------- ------- ---------- ----------- Industrial Revenues 66.9 86.1 66.9 86.1 -22.3% -22.3% ---------- --------- ------- ------- ---------- ----------- Scapa Group Revenues 122.0 160.8 118.3 157.2 -24.1% -24.7% ---------- --------- ------- ------- ---------- -----------
Working capital management remains strong, with adjusted net debt(3) at the end of FY21 H1 of GBP21.8m (including net proceeds of GBP31.6m from the equity placement in May 2020), compared to the FY20 year-end position of GBP54.4m.
The combination of the better than anticipated business performance in FY21 H1, cost containment actions and continued improvement across both divisions has put the Group on a solid foundation as it enters FY21 H2. Further details on expectations for the full year trading performance will be provided with the interim results on 17 November 2020.
(1) Group results before the impact of IFRS 15 provision release for the Systagenix acquisition
(2) ConvaTec revenues in FY20 were GBP3.5m, excluding this the change versus prior year is 22.6% on a statutory basis
(3) Adjusted net debt excludes the IFRS16 impact of lease liabilities
For further information:
Scapa Group plc Heejae Chae - Group Chief Executive Tel: 0161 301 Oskar Zahn - Chief Financial 7430 Officer Numis Securities Limited Mark Lander, Freddie Barnfield Tel: 020 7260 (Nominated Adviser/Joint 1000 Broker) ------------------------------------ -------------- Berenberg Chris Bowman, Toby Flaux Tel: 020 3207 (Joint Broker) 7800 ------------------------------------ -------------- FTI Consulting Simon Conway, Victoria Foster Tel: 020 3727 (Media Relations) Mitchell 1000 ------------------------------------ --------------
About Scapa Group plc
Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.
Healthcare
Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.
For further information, please visit www.scapahealthcare.com
Industrial
Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.
For further information, please visit www.scapaindustrial.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTKKBBNNBDDNKD
(END) Dow Jones Newswires
October 13, 2020 02:00 ET (06:00 GMT)
1 Year Scapa Chart |
1 Month Scapa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions